LLY

719.2

-0.72%↓

UNH

261.78

-16.67%↓

ABBV

177.65

-1.76%↓

NVO

65.59

+1.39%↑

ABT

132.13

+2.14%↑

LLY

719.2

-0.72%↓

UNH

261.78

-16.67%↓

ABBV

177.65

-1.76%↓

NVO

65.59

+1.39%↑

ABT

132.13

+2.14%↑

LLY

719.2

-0.72%↓

UNH

261.78

-16.67%↓

ABBV

177.65

-1.76%↓

NVO

65.59

+1.39%↑

ABT

132.13

+2.14%↑

LLY

719.2

-0.72%↓

UNH

261.78

-16.67%↓

ABBV

177.65

-1.76%↓

NVO

65.59

+1.39%↑

ABT

132.13

+2.14%↑

LLY

719.2

-0.72%↓

UNH

261.78

-16.67%↓

ABBV

177.65

-1.76%↓

NVO

65.59

+1.39%↑

ABT

132.13

+2.14%↑

Search

Johnson and Johnson

Open

SectorHealthcare

148.98 1.56

Overview

Share price change

24h

Current

Min

146.12

Max

149.25

Key metrics

By Trading Economics

Income

7.6B

11B

Sales

-627M

22B

P/E

Sector Avg

17.146

56.602

EPS

2.77

Dividend yield

3.37

Profit margin

50.24

Employees

138,100

EBITDA

9.7B

16B

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+15.81% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

3.37%

2.45%

Next Earnings

16 Jul 2025

Next Dividend date

10 Jun 2025

Next Ex Dividend date

27 May 2025

Market Stats

By TradingEconomics

Market Cap

-6.3B

371B

Previous open

147.42

Previous close

148.98

News Sentiment

By Acuity

30%

70%

86 / 382 Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

Johnson and Johnson Chart

Past performance is not a reliable indicator of future results.

Related News

9 May 2025, 17:03 UTC

Earnings
Major Market Movers

Anika Therapeutics Shares Fall After Slump in 1Q Pain-Treatment Sales in U.S.

15 Apr 2025, 15:12 UTC

Earnings

J&J Boosts Outlook Despite Incoming Tariff Costs -- Update

15 Apr 2025, 10:35 UTC

Top News
Earnings

J&J Increases Outlook After Beating 1Q Expectations

12 May 2025, 22:14 UTC

Top News

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12 May 2025, 18:45 UTC

Top News

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

12 May 2025, 17:14 UTC

Top News

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- WSJ

7 May 2025, 09:30 UTC

Top News

Trump Is Threatening Big Pharma With Tariffs. Tax Changes Might Work Better. -- Heard on the Street -- WSJ

4 May 2025, 04:05 UTC

Acquisitions, Mergers, Takeovers

UnitedHealth's Stock Is Ailing. A Bigger Business Hasn't Helped. -- Barrons.com

18 Apr 2025, 11:00 UTC

Top News

Johnson & Johnson Pivots Its AI Strategy -- WSJ

17 Apr 2025, 20:34 UTC

Earnings

UnitedHealth Woes Aren't Dragging Down the Entire Sector. Here's Why. -- Barrons.com

17 Apr 2025, 18:24 UTC

Earnings

UnitedHealth Woes Aren't Dragging Down the Entire Sector. Here's Why. -- Barrons.com

15 Apr 2025, 19:06 UTC

Earnings

These Stocks Are Moving the Most Today: Bank of America, Citigroup, Netflix, Boeing, Tesla, HPE, Applied Digital, and More -- Barrons.com

15 Apr 2025, 18:52 UTC

Market Talk
Earnings

J&J's 1Q Performance Signals Positive Outlook for MedTech Sector -- Market Talk

15 Apr 2025, 14:54 UTC

Earnings

Why Johnson & Johnson Stock Is Down After Earnings Beat Expectations -- Barrons.com

15 Apr 2025, 13:19 UTC

Earnings
Acquisitions, Mergers, Takeovers

Why Johnson & Johnson Stock Is Down After Earnings Beat Expectations -- Barrons.com

15 Apr 2025, 11:52 UTC

Earnings

Johnson & Johnson Tops Earnings Estimates and Boosts Outlook. The Stock Slips. -- Barrons.com

15 Apr 2025, 11:14 UTC

Earnings

Johnson & Johnson Tops Earnings Estimates and Boosts Outlook. The Stock Slips. -- Barrons.com

15 Apr 2025, 10:51 UTC

Earnings

These Stocks Are Moving the Most Today: Boeing, Tesla, Bank of America, J&J, Netflix, Allegro MicroSystems, and More -- Barrons.com

15 Apr 2025, 10:37 UTC

Top News
Earnings

Johnson & Johnson Tops Earnings Estimates and Boosts Outlook. The Stock Rises. -- Barrons.com

15 Apr 2025, 10:20 UTC

Earnings

Johnson & Johnson Now Sees 2025 Operational Sales of $91.6B-$92.4B Vs. Prior Outlook $90.9B-$91.7B >JNJ

15 Apr 2025, 10:20 UTC

Earnings

Johnson & Johnson Backs 2025 Adj EPS $10.50-Adj EPS $10.70 >JNJ

15 Apr 2025, 10:20 UTC

Earnings

Johnson & Johnson Raises 2025 View To Sales $91B-$91.8B Vs Prior View $89.2B-$90B >JNJ

15 Apr 2025, 10:20 UTC

Earnings

Johnson & Johnson Now Sees 2025 Adjusted Operational EPS $10.50-$10.70 Vs Prior View $10.75-$10.95 >JNJ

15 Apr 2025, 10:20 UTC

Earnings

Johnson & Johnson: Including Tariff Costs, Dilution From Intra-Cellular Therapies Buy and Updated Forex, Maintain FY Adj EPS Outlook of 6.2% Growth at Mid-Point >JNJ

15 Apr 2025, 10:20 UTC

Earnings

Johnson & Johnson: Strong 1Q Operational Sales Growth Reinforces Our Confidence in 2025 Guidance >JNJ

15 Apr 2025, 10:20 UTC

Earnings

Johnson & Johnson 1Q Sales $21.89B >JNJ

15 Apr 2025, 10:20 UTC

Earnings

Johnson & Johnson: Increasing FY25 Operational Sales Guidance to Reflect Addition of Caplyta Following Completion of Intra-Cellular Therapies Acquisition >JNJ

15 Apr 2025, 10:20 UTC

Earnings

Johnson & Johnson 1Q Worldwide MedTech Sales $8.02B >JNJ

15 Apr 2025, 10:20 UTC

Earnings

Johnson & Johnson 1Q International Sales $9.59B >JNJ

15 Apr 2025, 10:20 UTC

Earnings

Johnson & Johnson 1Q Adj EPS $2.77 >JNJ

Peer Comparison

Price change

Johnson and Johnson Forecast

Price Target

By TipRanks

15.81% upside

12 Months Forecast

Average 169.5 USD  15.81%

High 185 USD

Low 153 USD

Based on 15 Wall Street analysts offering 12 month price targets forJohnson and Johnson - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

15 ratings

7

Buy

8

Hold

0

Sell

Technical Score

By Trading Central

154.93 / 155.895Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Weak Bullish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

86 / 382 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Johnson and Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.